Telix Pharmaceuticals (NASDAQ:TLX) Sees Strong Trading Volume – Still a Buy?

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) saw an uptick in trading volume on Monday . 198,627 shares were traded during mid-day trading, an increase of 126% from the previous session’s volume of 87,898 shares.The stock last traded at $7.8350 and had previously closed at $8.03.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on TLX shares. Wall Street Zen lowered shares of Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Citigroup began coverage on Telix Pharmaceuticals in a research report on Thursday, September 18th. They issued a “buy” rating and a $22.00 target price for the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Wednesday, October 8th. Canaccord Genuity Group upgraded Telix Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 6th. Finally, UBS Group cut their price objective on Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Telix Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $21.00.

Telix Pharmaceuticals Trading Down 3.4%

The business has a 50-day moving average of $9.43 and a 200-day moving average of $11.39.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Pier Capital LLC acquired a new position in Telix Pharmaceuticals during the second quarter worth $3,037,000. Blair William & Co. IL acquired a new position in shares of Telix Pharmaceuticals during the 2nd quarter valued at about $217,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Telix Pharmaceuticals in the 2nd quarter worth approximately $297,000. Portland Investment Counsel Inc. acquired a new position in Telix Pharmaceuticals in the 3rd quarter valued at $1,225,000. Finally, Millennium Management LLC acquired a new position in shares of Telix Pharmaceuticals during the 3rd quarter worth about $1,883,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.